Phase 3 Study to Evaluate the Immunogenicity and Safety of Inactivated Split Influenza Vaccine in Healthy Korea Adults
A Multicenter, Open-Label, Phase 3 Clinical Study to Evaluate the Immunogenicity and Safety of IL-YANG Inactivated Split Influenza Vaccine in Healthy Adults 18 to < 65 Years of Age and in Healthy Adults ≥ 65 Years of Age.
研究概览
详细说明
This is a multicenter, open-label study. Subjects who have provided written informed consent will undergo the protocol-specific assessments to determine their eligibility for the study. Subjects considered eligible will be assigned to an appropriate age stratum, and will be given a single dose of the study vaccine. For each age stratum, the first 142 subjects enrolled will be evaluated for both immunogenicity and safety, and the remaining subjects subsequently enrolled will be evaluated only for the safety of the study vaccine.
- Group A: healthy adults 18 to < 65 years of age
- Group B: healthy adults ≥ 65 years of age
The investigator will evaluate the immunogenicity and safety of the study vaccine throughout the study. The immunogenicity assessment will be performed at Visit 1 (pre-vaccination) and at the End-of-Study Visit. For safety measurements, subjects will be instructed to record any adverse events occurring after vaccination in the Patient Diary card.
Subjects who are assigned for the both immunogenicity and safety assessment will have their blood sample drawn for antibody titer (immunogenicity) testing, and afterward, receive 0.5 mL of the study vaccine by intramuscular injection at deltoid muscle. Subjects will return to the clinic for follow-up visit 4 to 5 weeks after the vaccination, and undergo another blood sampling for antibody titer test. The long-term safety for up to 6 months after vaccination will be also evaluated. Subjects who are assigned for only safety assessments will not undergo blood sampling, but have the same visit schedule as those assigned for the both immunogenicity and safety assessments.
研究类型
注册 (实际的)
阶段
- 第三阶段
联系人和位置
学习地点
-
-
-
Seoul etc、大韩民国
- Incheon St. Mary's Hospital, The Catholic University of Korea etc, Total 10 hospitals.
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Healthy man and woman 18 years of age or older
- Woman of childbearing potential must have a negative urine human chorionic gonadotropin (HCG) test at screening
- Subject who was given, and fully understood, the information about the study, made a voluntary decision, and provided written informed consent, to participate in the study and comply with all applicable study requirements.
Exclusion Criteria:
- Subject with a known allergy to eggs, chicken, neomycin, gentamicin or any components of the study vaccine
- Subject who had received an influenza vaccine within the last 6 months
- Subject who has, or has a family history of, an immune system disorder including immune deficiency disease
- Subject who had participated in blood donation within 1 week prior to vaccination, or is planning to participate in blood donation from Day 1 until Month 7 post-vaccination.
- Subject with a history of Guillain-Barre syndrome
- Subject with Down's syndrome or cytogenetic disorders.
- Subject with severe chronic disease which in the investigator's opinion would not make the subject a good candidate for the clinical trial
- Subject with hemophilia or being treated with an anticoagulant, who are at increased risk of serious bleeding during intramuscular injection
- Subject who had an acute fever with body temperature > 38.0 Cº within 72 hours prior to administration of the study vaccine
- Subject who had received any product containing acetylsalicylic acid or aspirin within 14 days prior to administration of the study vaccine
- Subject who had previously received another vaccine within 28 days before administration of the study drug, or is scheduled to receive another vaccine during the study period.
- Subject who had received immunosuppressant or immune modifying drug within the last 3 months prior to administration of the study vaccine
- Subject who had previously received immunoglobulin or blood-derived products within the last 3 months prior to administration of the study vaccine, or is expecting to be treated with immunoglobulin or blood-derived products during the study.
- Subject who had participated in another experimental study within 30 days prior to administration of the study vaccine
- Woman of childbearing potential at screening or woman who plans to become pregnant during the study. A woman of childbearing potential must have a negative pregnancy test, and, unless surgically sterile, must use an effective method of contraception throughout the study to be eligible for the study. Periodic abstinence and withdrawal are not considered as acceptable methods of contraception. Use of hormonal contraceptives is not allowed.
- Subject with other clinically significant medical or psychological condition who in the investigator's opinion would not be suitable for the study.
学习计划
研究是如何设计的?
设计细节
- 主要用途:预防
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
实验性的:IL-YANG influenza vaccine
IL-YANG FLU Vaccine Prefilled Syringe INJ 0.5mL by intramuscular injection
|
IL-YANG FLU Vaccine Prefilled Syringe INJ 0.5mL by intramuscular injection
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Solicited local & general Adverse Event, Unsolicited Adverse Event
大体时间:up to Day28(+7)
|
Solicited local reaction: pain, tenderness, redness, swelling Solicited general reactions: fever, nausea/vomiting, diarrhea, headache, fatigue, myalgia
|
up to Day28(+7)
|
接种研究疫苗后实现 HI 抗体血清转化和血清保护的受试者百分比
大体时间:最多 Day28(+7)
|
血清转化:接种前(第 0 天)血凝抑制 (HI) 抗体滴度 < 1:10 和接种后(第 28 天)HI 抗体滴度 ≥ 1: 40(案例 1),或接种前(第 1 天) 0) HI 抗体滴度 ≥ 1:10 并且接种后(第 28 天)HI 抗体滴度至少增加四倍(案例 2)。 血清保护:接种疫苗后(第 28 天)HI 抗体滴度 ≥ 1:40 |
最多 Day28(+7)
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Physical examination finding, vital signs
大体时间:Day28(+7)
|
Day28(+7)
|
|
Geometric Mean Titer (GMT) of HI antibody titer before vaccination and after vaccination
大体时间:Day28(+7)
|
Geometric Mean Titer (GMT) and Geometric Mean Ratio (GMR), as measured by pre-vaccination (Day 0) HI antibody titer and post-vaccination (vaccination + 28 days) HI antibody titer.
|
Day28(+7)
|
Percentage of subjects with a pre-vaccination (Day 0) HI antibody titer < 1:40, and a minimum four-fold rise in post-vaccination (Day 28) HI antibody titer
大体时间:Day28(+7)
|
Day28(+7)
|
合作者和调查者
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.